Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brompheniramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | SCN1A | P35498 | 3/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 3/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexbrompheniramine SCHEMBL15516617 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1CHRM1 | |
| Brompheniramine SCHEMBL15516706 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1CHRM1 | |
| Brompheniramine SCHEMBL30182709 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1CHRM1 | |
| Brompheniramine SCHEMBL4814 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1CHRM1 | |
| Brompheniramine SCHEMBL4314531 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1CHRM1 | |
| Dexbrompheniramine SCHEMBL29345 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1CHRM1 | |
| Brompheniramine SCHEMBL6859988 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1CHRM1 | |
| Dexbrompheniramine SCHEMBL28086608 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1CHRM1 | |
| Dexbrompheniramine SCHEMBL3744666 | 0.94 | CHRM2 (0.88) | CHRM2SLC6A2SLC6A4HRH1CHRM1 | |
| Brompheniramine SCHEMBL1901052 | 0.94 | CHRM2 (0.88) | CHRM2SLC6A2SLC6A4HRH1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017846-A1 | TOPICAL ANALGESICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-16 | — | — | US | claimed |
| US-20190282792-A1 | COMPOUNDS FOR USE IN METHODS FOR TREATING GLAUCOMA AND RETINAL DISEASES | P&X MEDICAL NV (BE) | 2019-09-19 | — | — | US | claimed |
| EP-3487519-A1 | COMPOUNDS FOR USE IN METHODS FOR TREATING GLAUCOMA AND RETINAL DISEASES | P&X Medical NV (BE) | 2019-05-29 | — | — | EP | claimed |
| WO-2018015467-A1 | COMPOUNDS FOR USE IN METHODS FOR TREATING GLAUCOMA AND RETINAL DISEASES | P&X MEDICAL NV (BE) | 2018-01-25 | — | — | WO | claimed |
| WO-2014093228-A1 | ANTAGONIZING HEPARIN WITH SALICYLAMIDE COMPOUNDS AND ANTIHISTAMINES | CELLCEUTIX CORPORATION (US) | 2014-06-19 | — | — | WO | claimed |
| US-20140162955-A1 | Antagonizing Heparin With Salicylamide Compounds And Histamine Blocking Agents | CELLCEUTIX CORPORATION (US) | 2014-06-12 | — | — | US | claimed |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | MENG CHARLES Q | 2006-11-16 | — | — | US | claimed |
| US-7078431-B2 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS, INC. (US) | 2006-07-18 | — | — | US | claimed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-12311035-B2 | Glymphatic delivery by manipulating plasma osmolarity | UNIVERSITY OF ROCHESTER (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250144060-A1 | COMPOSITIONS AND METHODS FOR TREATING BIOFILMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-08 | — | — | US | disclosed |
| US-12226386-B2 | Compositions and methods for treating biofilms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| EP-0152432-B1 | SUSTAINED RELEASE METHOD AND PRODUCT | R.P. SCHERER CORPORATION (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4800083-A | MASTICATORY SUBSTANCE, DRUG, GELATIN CAPSULE THAT DISSOLVES IN GASTRIC JUICES | R. P. SCHERER CORPORATION (US) | 1989-01-24 | — | — | US | disclosed |
| EP-0152432-A1 | SUSTAINED RELEASE METHOD AND PRODUCT. | SCHERER CORP R P (US) | 1985-08-28 | — | — | EP | disclosed |
| WO-1985000516-A1 | SUSTAINED RELEASE METHOD AND PRODUCT | R. P. SCHERER CORPORATION (US) | 1985-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226386-B2 | Compositions and methods for treating biofilms | ITGA2, IDUA, ITGA1 | HRH1 3334/4885CHRM2 3026/4885SLC6A2 2935/4885 |
| US-20250017846-A1 | TOPICAL ANALGESICS | OPRK1, OPRL1, OPRM1 | HRH1 15/4885CHRM2 433/4885SLC6A2 368/4885 |
| US-20250144060-A1 | COMPOSITIONS AND METHODS FOR TREATING BIOFILMS | ITGA2, IDUA, ITGA1 | HRH1 3334/4885CHRM2 3026/4885SLC6A2 2935/4885 |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | HRH1 513/4885CHRM2 726/4885SLC6A2 3185/4885 |
| US-20140162955-A1 | Antagonizing Heparin With Salicylamide Compounds And Histamine Blocking Agents | HRH2, HRH4, HRH3 | HRH1 4/4885CHRM2 2027/4885SLC6A2 910/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | HRH1 3405/4885CHRM2 4299/4885SLC6A2 3225/4885 |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | HRH1 513/4885CHRM2 726/4885SLC6A2 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.